SGK1
SGK1 (Serine/threonine-protein kinase Sgk1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 2 more.
Overview
Serine/threonine-protein kinase which is involved in the regulation of a wide variety of ion channels, membrane transporters, cellular enzymes, transcription factors, neuronal excitability, cell growth, proliferation, survival, migration and apoptosis. Plays an important role in cellular stress response. Contributes to regulation of renal Na(+) retention, renal K(+) elimination, salt appetite, gastric acid secretion, intestinal Na(+)/H(+) exchange and nutrient transport, insulin-dependent salt sensitivity of blood pressure, salt sensitivity of peripheral glucose uptake, cardiac repolarisation and memory consolidation.
CIViC holds 4 clinical evidence items and 0 assertions across 2 variants, naming Alpelisib and SGK1-Inh. IntOGen calls it a driver in 6 cohorts (4 activating, 2 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma, Papillary Renal Cell Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · SGK1 (Serine/threonine-protein kinase Sgk1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 2 more.
- 1 · What it is
SGK1 (Serine/threonine-protein kinase Sgk1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 2 more.
- 2 · What goes wrong in cancer
Serine/threonine-protein kinase which is involved in the regulation of a wide variety of ion channels, membrane transporters, cellular enzymes, transcription factors, neuronal excitability, cell growth, proliferation, survival, migration and apoptosis.
- 3 · How drugs use it
No product in this corpus aims at SGK1 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
External identifiers
Sources: HGNC HGNC:10810 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O00141 (protein name, function text, keywords and locations (REST API)); CIViC gene SGK1 (4 evidence items, 0 assertions, 2 variants; diseases: Breast Cancer, Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000118515 (per-cancer scores at or above 0.5: diffuse large B-cell lymphoma 0.53, non-Hodgkin lymphoma 0.55 (GraphQL API, CC0)); IntOGen SGK1 (driver in 6 cohorts (Act 4, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Serine/threonine-protein kinase which is involved in the regulation of a wide variety of ion channels, membrane transporters, cellular enzymes, transcription factors, neuronal excitability, cell growth, proliferation, survival, migration and apoptosis. Plays an important role in cellular stress response. Contributes to regulation of renal Na(+) retention, renal K(+) elimination, salt appetite, gastric acid secretion, intestinal Na(+)/H(+) exchange and nutrient transport, insulin-dependent salt sensitivity of blood pressure, salt sensitivity of peripheral glucose uptake, cardiac repolarisation and memory consolidation. Up-regulates Na(+) channels: SCNN1A/ENAC, SCN5A and ASIC1/ACCN2, K(+) channels: KCNJ1/ROMK1, KCNA1-5, KCNQ1-5 and KCNE1, epithelial Ca(2+) channels: TRPV5 and TRPV6, chloride channels: BSND, CLCN2 and CFTR, glutamate transporters: SLC1A3/EAAT1, SLC1A2 /EAAT2, SLC1A1/EAAT3, SLC1A6/EAAT4 and SLC1A7/EAAT5, amino acid transporters: SLC1A5/ASCT2, SLC38A1/SN1 and SLC6A19, creatine transporter: SLC6A8, Na(+)/dicarboxylate cotransporter: SLC13A2/NADC1, Na(+)-dependent phosphate cotransporter: SLC34A2/NAPI-2B, glutamate receptor: GRIK2/GLUR6. Up-regulates carriers: SLC9A3/NHE3, SLC12A1/NKCC2, SLC12A3/NCC, SLC5A3/SMIT, SLC2A1/GLUT1, SLC5A1/SGLT1 and SLC15A2/PEPT2. Regulates enzymes: GSK3A/B, PMM2 and Na(+)/K(+) ATPase, and transcription factors: CTNNB1 and nuclear factor NF-kappa-B. Location: Cytoplasm; Nucleus; Endoplasmic reticulum membrane; Cell membrane (UniProt). Locus 6q23.2 (HGNC).
- Breast cancer: CIViC evidence names this disease
- Non-Hodgkin lymphoma: Open Targets association 0.55 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL)
- Renal cell carcinoma: IntOGen driver in 1 cohort (PRCC)
- Diffuse large B-cell lymphoma: Open Targets association 0.53 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease
- Papillary renal cell carcinoma: IntOGen driver in 1 cohort (PRCC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; IntOGen calls it an activating (Act) driver in 4 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 4 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"SGK1" OR ABSTRACT:"SGK1" OR TITLE:"serum/glucocorticoid regulated kinase 1" OR ABSTRACT:"serum/glucocorticoid regulated kinase 1" OR TITLE:"Serine/threonine-protein kinase Sgk1" OR ABSTRACT:"Serine/threonine-protein kinase Sgk1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SGK1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPCBP1
Shares Papillary renal cell carcinoma, Renal cell carcinoma, Non-Hodgkin lymphoma (all types), CIViC.
- TargetCUL3
Shares Papillary renal cell carcinoma, Renal cell carcinoma, CIViC, IntOGen.
- TargetFLCN
Shares Papillary renal cell carcinoma, Renal cell carcinoma, CIViC, IntOGen.
- TargetNUP214
Shares Papillary renal cell carcinoma, Renal cell carcinoma, Non-Hodgkin lymphoma (all types), IntOGen.
- TargetCHD2
Shares Papillary renal cell carcinoma, Renal cell carcinoma, Non-Hodgkin lymphoma (all types), IntOGen.
- TargetPRDM2
Shares Papillary renal cell carcinoma, Renal cell carcinoma, IntOGen.
- TargetHNF1A
Shares Papillary renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
- TargetZHX2
Shares Papillary renal cell carcinoma, CIViC.